Additional indication for Revanex granted

Published: 2006-06-28 06:57:00

Updated: 2006-06-28 06:57:00

The Korean Food and Drug Administration (KFDA) said on June 26 it has granted Yuhan Corp. an additional indication for their novel proton pump inhibitor Revanex (revaprazan).

Revanex is now indicated for the prevention of gastritis and its prior indication included its use for the prevention o...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK